Rani Therapeutics
RANI
35 hedge funds and large institutions have $13.3M invested in Rani Therapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 2 reducing their positions, and 4 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 2
0.58% more ownership
Funds ownership: 12.13% → 12.72% (+0.58%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
3% less funds holding
Funds holding: 36 → 35 (-1)
14% less capital invested
Capital invested by funds: $15.5M → $13.3M (-$2.22M)
75% less call options, than puts
Call options by funds: $13K | Put options by funds: $51K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$737K |
| 2 |
Millennium Management
New York
|
+$273K |
| 3 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$261K |
| 4 |
Renaissance Technologies
New York
|
+$219K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$191K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$365K |
| 2 |
Goldman Sachs
New York
|
-$173K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$103K |
| 4 |
IWP
Icon Wealth Partners
Houston,
Texas
|
-$65.8K |
| 5 |
CL
Choreo LLC
Rockford,
Illinois
|
-$23.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $26.9K | +$23.6K | +5,082 | +352% |
|
27
UBS Group
Zurich,
Switzerland
| $16.5K | +$14K | +3,012 | +301% |
|
|
AF
28
Allworth Financial
Folsom,
California
| $12.9K | – | – | – |
|
29
Morgan Stanley
New York
| $7.87K | +$6.41K | +1,380 | +260% |
|
30
Simplex Trading
Chicago,
Illinois
| $6K | +$5.6K | +1,206 | +350% |
|
|
IWP
31
IAG Wealth Partners
Waukesha,
Wisconsin
| $4.14K | +$4.67K | +1,005 | New |
|
32
RhumbLine Advisers
Boston,
Massachusetts
| $1.28K | +$1.45K | +312 | New |
|
|
FCA
33
FinTrust Capital Advisors
Greenville,
South Carolina
| $443 | – | – | – |
|
34
Wells Fargo
San Francisco,
California
| $317 | +$23 | +5 | +7% |
|
|
35
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$365K | -70,772 | Closed |
|
|
36
Goldman Sachs
New York
| – | -$173K | -33,532 | Closed |
|
|
37
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$103K | -19,907 | Closed |
|
|
IWP
38
Icon Wealth Partners
Houston,
Texas
| – | -$65.8K | -12,757 | Closed |
|
RANI Hedge Fund Activity: Q2 2023 in Review
35 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q2 2023, worth a combined $13.3M — down 14% from $15.5M a quarter earlier.
Fund positioning in RANI was balanced in Q2 2023: 4 funds opened new positions, 4 closed out, 12 added to existing stakes and 2 trimmed.
The largest buyer was Bank of America, adding an estimated $737K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $365K sold.
- 35 institutional investors held Rani Therapeutics (RANI) as of Q2 2023, down from 36 in Q1 2023.
- Funds reported $13.3M of Rani Therapeutics stock for Q2 2023, down 14% quarter-over-quarter.
- 4 funds opened new Rani Therapeutics positions in Q2 2023 and 4 closed out, a net change of 0 holders.
- The largest Rani Therapeutics buyer in Q2 2023 was Bank of America, an estimated $737K added.
- The largest Rani Therapeutics seller in Q2 2023 was Susquehanna International Group, an estimated $365K sold.
Based on aggregated 13F filings for Q2 2023.